Atea Pharmaceuticals, Inc is a biotechnology business based in the US. Atea Pharmaceuticals shares (AVIR) are listed on the NASDAQ and all prices are listed in US Dollars. Atea Pharmaceuticals employs 42 staff and has a trailing 12-month revenue of around 0.00.
How to buy shares in Atea Pharmaceuticals
- Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
- Open your brokerage account. Complete an application with your details.
- Confirm your payment details. Fund your account.
- Research the stock. Find the stock by name or ticker symbol – AVIR – and research it before deciding if it's a good investment for you.
- Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
- Check in on your investment. Optimize your portfolio by tracking your stock.
Atea Pharmaceuticals stock price (NASDAQ: AVIR)Use our graph to track the performance of AVIR stocks over time.
Atea Pharmaceuticals shares at a glance
|Latest market close||$20.42|
|52-week range||$18.72 - $90.95|
|50-day moving average||$23.51|
|200-day moving average||$45.82|
|Wall St. target price||$35.00|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||$0.57|
Buy Atea Pharmaceuticals shares from these brokeragesCompare special offers, low fees and a wide range of types of investments among top trading platforms.
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
Is it a good time to buy Atea Pharmaceuticals stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Atea Pharmaceuticals price performance over time
|1 week (2021-07-20)||N/A|
|1 month (2021-07-01)||-4.27%|
|3 months (2021-04-30)||-17.36%|
|6 months (2021-01-27)||N/A|
|1 year (2020-07-27)||N/A|
|2 years (2019-07-27)||N/A|
|3 years (2018-07-27)||N/A|
|5 years (2016-07-27)||N/A|
Is Atea Pharmaceuticals under- or over-valued?
Valuing Atea Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Atea Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Atea Pharmaceuticals's P/E ratio
Atea Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 44x. In other words, Atea Pharmaceuticals shares trade at around 44x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
However, Atea Pharmaceuticals's P/E ratio is best considered in relation to those of others within the biotechnology industry or those of similar companies.
Atea Pharmaceuticals's EBITDA
Atea Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $41.7 million.
The EBITDA is a measure of a Atea Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.
To put Atea Pharmaceuticals's EBITDA into context you can compare it against that of similar companies.
Atea Pharmaceuticals financials
|Revenue TTM||$114.6 million|
|Operating margin TTM||36.34%|
|Gross profit TTM||$10.6 million|
|Return on assets TTM||6.07%|
|Return on equity TTM||7.89%|
|Market capitalisation||$2.1 billion|
TTM: trailing 12 months
Shorting Atea Pharmaceuticals shares
There are currently 8.7 million Atea Pharmaceuticals shares held short by investors – that's known as Atea Pharmaceuticals's "short interest". This figure is 72.2% up from 5.0 million last month.
There are a few different ways that this level of interest in shorting Atea Pharmaceuticals shares can be evaluated.
Atea Pharmaceuticals's "short interest ratio" (SIR)
Atea Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Atea Pharmaceuticals shares currently shorted divided by the average quantity of Atea Pharmaceuticals shares traded daily (recently around 1.9 million). Atea Pharmaceuticals's SIR currently stands at 4.54. In other words for every 100,000 Atea Pharmaceuticals shares traded daily on the market, roughly 4540 shares are currently held short.
To gain some more context, you can compare Atea Pharmaceuticals's short interest ratio against those of similar companies.
However Atea Pharmaceuticals's short interest can also be evaluated against the total number of Atea Pharmaceuticals shares, or, against the total number of tradable Atea Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Atea Pharmaceuticals's short interest could be expressed as 0.11% of the outstanding shares (for every 100,000 Atea Pharmaceuticals shares in existence, roughly 110 shares are currently held short) or 0.1739% of the tradable shares (for every 100,000 tradable Atea Pharmaceuticals shares, roughly 174 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Atea Pharmaceuticals.
Find out more about how you can short Atea Pharmaceuticals stock.
Atea Pharmaceuticals share dividends
We're not expecting Atea Pharmaceuticals to pay a dividend over the next 12 months.
You may also wish to consider:
- Gilead Sciences (GILD.US) (3.93% forward annual dividend yield)
- GlaxoSmithKline (GSK.US) (2.02% forward annual dividend yield)
- Novartis (NVS.US) (3.72% forward annual dividend yield)
Atea Pharmaceuticals overview
Atea Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States.
Stocks similar to Atea Pharmaceuticals
Atea Pharmaceuticals in the news
Atea Pharmaceuticals participates in a conference call with JPMorgan
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
Atea Pharmaceuticals to Present at William Blair Biotech Focus Conference
Frequently asked questionsWhat percentage of Atea Pharmaceuticals is owned by insiders or institutions?
Currently 18.494% of Atea Pharmaceuticals shares are held by insiders and 63.457% by institutions. How many people work for Atea Pharmaceuticals?
Latest data suggests 42 work at Atea Pharmaceuticals. When does the fiscal year end for Atea Pharmaceuticals?
Atea Pharmaceuticals's fiscal year ends in December. Where is Atea Pharmaceuticals based?
Atea Pharmaceuticals's address is: 125 Summer Street, Boston, MA, United States, 02110
More guides on Finder
How to buy Argus Capital Corp (ARGU) stock when it goes public
Everything we know about the Argus Capital Corp IPO, plus information on how to buy in.
How to buy RenovoRx (RNXT) stock when it goes public
Everything we know about the RenovoRx IPO, plus information on how to buy in.
How to buy Draganfly (DPRO) stock when it goes public
Everything we know about the Draganfly IPO, plus information on how to buy in.
How to buy Society Pass Incorporated (SOPA) stock when it goes public
Everything we know about the Society Pass Incorporated IPO, plus information on how to buy in.
How to buy Guardforce AI Co (GFAI) stock when it goes public
Everything we know about the Guardforce AI Co IPO, plus information on how to buy in.
How to buy IsoPlexis Corporation (ISO) stock when it goes public
Everything we know about the IsoPlexis Corporation IPO, plus information on how to buy in.
How to buy Marpai (MRAI) stock when it goes public
Everything we know about the Marpai IPO, plus information on how to buy in.
How to buy DoubleDown Interactive (DDI) stock when it goes public
Everything we know about the DoubleDown Interactive IPO, plus information on how to buy in.
How to buy Omniq Corp (OMQS) stock when it goes public
Everything we know about the Omniq Corp IPO, plus information on how to buy in.
How to buy Mechanical Technology (MKTYP) stock when it goes public
Everything we know about the Mechanical Technology IPO, plus information on how to buy in.
Ask an Expert